Abacus Health Products Announces First Purchase Order from a Major US Retail Chain

Published: March 1, 2019

Abacus Health Products Announces First Purchase Order from a Major US Retail Chain

Abacus Health Products, Inc. announced its first purchase order received from a major United States retail chain. These products – expected to be on the shelves of select stores in the coming weeks – will mark the first time the CBDMEDIC family of products will be available to consumers in a retail store format.

“This purchase order marks an important milestone in our growth strategy of securing major US retail chains to distribute our products,” said Perry Antelman, CEO of Abacus. “These stores are an initial step toward our ultimate goal of distributing our Over-The-Counter (OTC) registered products through major retail chains from coast to coast and represents a major inflection point in the accessibility of CBDMEDIC to the American market.”

Abacus has developed a range of innovative products based on patent-pending technologies which combine natural and organic ingredients, including a cannabinoid-rich hemp extract containing CBD from the Cannabis sativa L plant. These OTC-registered medications are aimed at the large and growing markets for topical pain relief and therapeutic skincare.

Abacus believes that the pain management and skincare markets represent medical areas with substantial unmet needs, and that its CBDMEDIC line of products offer powerful, all-natural alternatives to existing products. The American Academy of Pain Medicine has estimated that chronic pain affects approximately 100 million Americans. Further, a 2018 research report by Allied Market Research estimated the global topical pain relief market to be approximately US$7.4 billion in 2017.

According to the American Academy of Dermatology Association over 84.5 million Americans are impacted by a form of skin disease and the total estimated cost of skin diseases include US$15 billion in prescription drugs and US$10 billion in OTC products.